Roche Holding AG has taken the surprising step of jumping into the cardiovascular space and teamed up with Alnylam Pharmaceuticals Inc. to co-develop and co-commercialize zilebesiran, the RNA interference (RNAi) specialist's keenly-watched twice-yearly injection for hypertension.
The Swiss giant is paying $310m upfront while Alnylam is eligible to receive additional "substantial" near-term and development milestone payments...